Drug Trial Radar · NCT05750589
Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections
Last checked: Nov 19, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Sep 1, 2026
Primary completion
Jan 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- iRenix Medical, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-masked study to evaluate the tolerability and safety of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections.
Conditions
- Retinal Disease
Interventions
IRX-101Drug
IRX-101 is a novel ocular anti-septic
Providone-IodineDrug
5% Providone-Iodine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of post-intravitreal injection eye painTime frame: Demonstrate a reduction in mean 1-hr post-injection pain scores
Locations
1 site in 1 country. Site status is shown where the registry gives one.
R. Gary Lane, II MD
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.